0
CohBar, Inc. Banner Image

CohBar, Inc.

  • Ticker CWBR
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
CohBar, Inc. Logo Image
  • 11-50 Employees
  • Based in Menlo Park, California
CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases. Mitochondria based therapeutics originate from the discovery by CohBar’s founders of a novel group of naturally occurring peptide sequences within the mitochondrial genomeMore, some of which have been shown to have the potential to regulate key processes in multiple systems and organs in the body. To date, the company has discovered more than 100 mitochondrial derived peptides and generated over 1,000 analogs. CohBar’s efforts focus on the development of these peptides into therapeutics that offer the potential to address a broad range of diseases because of the underlying impact of mitochondrial dysfunction. The company’s lead compound, CB4211, is in the Phase 1b stage of a Phase 1a/1b clinical trial for NASH and obesity. In addition, CohBar has four preclinical programs: CB5138 Analogs for fibrotic diseases, CB5064 Analogs for COVID-19 associated ARDS, MBT5 Analogs for CXCR4-related cancer and orphan diseases, and MBT3 Analogs for cancer immunotherapy.
REPORT RATINGS
4.8 / 5.0 (150)

CohBar, Inc. reports have an aggregate usefulness score of 4.8 based on 150 reviews.

CohBar, Inc.

Most Recent Annual Report

CohBar, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

CohBar, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!